-The Economic Times A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health. Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions. Last month, China amended its IP laws, allowing local companies to produce low-cost versions...

-The Economic Times   Pushed to the wall by an overly cautious drug regulator and an alarmist Indian government, clinical trial companies are looking at South East Asian countries to expand their business and escape the red tape of Indian authorities.  Clinical research companies (CROs), that were aspiring to become billion- dollar companies by 2010, had to rework their plans after a Parliamentary Standing Committee report questioned the allegedly unfair and unethical trials...

-The Hindu The World Health Organisation (WHO) has put in place a mechanism to define counterfeit medical products. The set of definitions of sub-standard, spurious, falsely labelled, falsified and counterfeit products will be globally accepted and help to bring about uniformity in identifying such drugs, without interrupting worldwide supplies. The decision to establish a member state mechanism was taken at the World Health Assembly, the WHO's policymaking body, at a meeting held recently. The...

The Conflict of Interest Bill introduced in the Rajya Sabha is a welcome step to control the grey areas in which “public private partnerships” are conducted. AMONG the many things that have proliferated in the economic boom of the brash new India is conflict of interest. So widespread, comprehensive and many-tentacled has this feature become that it is often no longer even recognised to exist, much less to be a...

It is said that only God and a few good men and women run India. One such man is P H Kurien. For readers unfamiliar with his name, Kurien was India's Controller General of Patents, Designs & Trade Marks until March 12, 2012. On March 9, 2012, just three days before he left office, he issued the first-ever compulsory licence in India for the manufacture of a drug still under patent....